Analysts Viewpoint
H.C. Wainwright upgrades Syros Pharmaceuticals Inc (SYRS) rating to a Buy
Syros Pharmaceuticals Inc’s recent filing unveils that its President & CEO Chee Conley acquired Company’s shares for reported $85420.0 on
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.